Not received an unlicensed investigational agent drug device or blood-derived product within 30 days prior to randomization and may not receive such an investigational agent in the 30 days post-randomization note investigational use for treatment of TMA of a licensed immunomodulator e.g. rituximab is permitted at any time relative to randomization 